At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 35 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
18F-AV-1451 PET Imaging in Professional Fighters
In Brief
A Phase 1 clinical trial evaluating Flortaucipir F18 and Brain PET scan for Alzheimer's Disease. Completed, enrolled 35 participants across 1 site.
Detailed Summary
Subjects enrolled in the Professional Fighters Brain Health Study (PFBHS) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between clinical presentation and tau deposition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsThe Cleveland Clinic
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartFeb 2015
Primary CompletionFeb 2017
TodayJul 2026
First PostedOct 30, 2014
Enrollment StartFeb 18, 2015
Primary CompletionFeb 3, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.7 years ago
Interventions
Flortaucipir F18drug
IV injection, 370 megabecquerel (MBq) (10 mCi)
Brain PET scanprocedure
positron emission tomography (PET) scan of the brain 75-105 minutes post injection